PubMed Health⌕ Search

Biomedical subjects

P Ohlsén

Publications and source records attributed to P Ohlsén.

7 recordsLinked to original sources

Influence of a beta2-agonist on physical performance at low temperature in elite athletes.

Beta2-agonists are frequently used by elite cross-country skiers, a group of athletes with a high prevalence of asthma. It has been claimed that beta2-agonists have a positive effect on physical performance. The aim of the present study was to investigate whether inhalation of a beta2-agonist increases physical performance at low temperature in healthy, nonasthmatic athletes with normal bronchial responsiveness. Twenty elite male athletes (cyclists, cross-country skiers, middle and long distance runners) with no history of allergy or airway disease and who had normal spirometry and methacholine bronchial provocation tests performed a maximal exercise test on a treadmill in a climate chamber at approximately 10 degrees C on two subsequent days. Before exercise they inhaled terbutaline (3 mg from MDI) or placebo in a randomized, single blind manner. After 10-min warm-up on the treadmill, a submaximal work preceded a stepwise increase of the workload until exhaustion. Lung function, ventilation, oxygen uptake, and heart rate were determined and blood samples for lactate and potassium analyses were drawn before, during, and after exercise. Terbutaline induced a significant bronchodilatation; FEV1 increased from 4.8 (4.4-5.1) L to 5.0 (4.6-5.4) L, mean (95% CI). There were no significant differences between the two treatments with regard to exercise time, 25.1 (24.3-25.8) min vs 24.9 (24.1-25.6) min, oxygen uptake and ventilation during exercise, or heart rate at maximal workload. Terbutaline induced an increase in serum lactate concentration but did not influence the lactate response to exercise. The serum potassium increase was attenuated at low workload but not at maximal work. The postexercise decrease in serum potassium concentration was significantly greater after terbutaline (-0.52 (-0.29 to -0.76) mmol x L-1) than after placebo (-0.13 (0.06 to -0.32) mmol x L-1 (P < 0.001). We conclude that inhalation of a beta2-agonist (terbutaline) in a dose that yields significant bronchodilatation does not influence physical performance at low temperature in healthy athletes. Acute inhalation of the beta2-agonist amplified the postexercise hypokalemia, a finding of unclear significance. Although there is a slight bronchodilatation and potential negative airways effect of cold air inhalation, a beta2-agonist does not increase physical performance in top athletes.

Adolescent↗

High prevalence of asthma in cross country skiers.

OBJECTIVES: To study the prevalence of asthma (asthma symptoms and bronchial hyperresponsiveness) in Swedish cross country skiers compared with non-skiers and monitor changes in symptoms and bronchial hyperresponsiveness during the year. DESIGN: Cross sectional study during the winter ski season and in the summer. SETTING: Six ski clubs for élite skiers (total 47) in two different areas of Sweden. SUBJECTS: 42 élite cross country skiers and 29 non-skiing referents. MAIN OUTCOME MEASURES: Bronchial responsiveness, asthma symptoms, and lung function. RESULTS: Bronchial responsiveness was significantly greater and asthma symptoms more prevalent in the skiers than in the referents. There was no difference in bronchial responsiveness within either group between winter and summer. 15 of the 42 skiers used antiasthmatic drugs regularly and 23 had a combination of asthma symptoms and hyperresponsive airways or physician diagnosed asthma, or both. Altogether 33 skiers had symptoms of asthma or bronchial hyperresponsiveness. One of the referents had symptoms of asthma and bronchial hyperresponsiveness, and none used antiasthmatic drugs regularly. CONCLUSIONS: Asthma, asthma-like symptoms, and bronchial hyperresponsiveness are much more common in cross country skiers than in the general population and non-skiers. Strenuous exercise at low temperatures entailing breathing large volumes of cold air is the most probable explanation of persistent asthma in skiers.

Adolescent↗

Extrapancreatic effects of a sulphonylurea. Decrease in xylose absorption by glipizide in type II diabetics.

The effects of glipizide on the absorption of glucose and d-xylose were studied in six type II diabetics on diet treatment alone. Glipizide was given intravenously (12 micrograms/kg at 0 min) or orally (5 mg at -30 min). Oral glucose (15 g) and xylose (25 g) loads were given at zero time. Glipizide stimulated insulin secretion and reduced glucose and xylose levels significantly with both routes of administration. The suppression of xylose levels lasted longer after oral than after intravenous administration of the drug. It is suggested that part of the influence of glipizide on postprandial glucose levels may represent interference with absorptive mechanisms.

Administration, Oral↗